Juergen Horn

An­i­mal health vet Juer­gen Horn makes new an­ti­body play for pets, rak­ing $15M in Se­ries A haul

Zoetis forked over $85 mil­lion in 2017 to ac­quire Nexvet Bio­phar­ma and its pipeline of mon­o­clon­al an­ti­bod­ies. Juer­gen Horn, Nexvet’s for­mer chief prod­uct de­vel­op­ment of­fi­cer, has now se­cured $15 mil­lion for his own bi­o­log­ic com­pa­ny for an­i­mals: In­vetx.

Buoyed by emerg­ing ad­vances in gene ther­a­pies for hu­mans, sci­en­tists have start­ed look­ing at har­ness­ing the tech­nol­o­gy for an­i­mals set­ting up com­pa­nies such as Penn-part­nered Scout Bio and George Church-found­ed Re­ju­ve­nate Bio. But akin to Nexvet, In­vetx is work­ing on lever­ag­ing the time-test­ed sci­ence of mon­o­clon­al an­ti­bod­ies to treat chron­ic dis­eases that af­flict man’s best friend.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.